Medipal Holdings Corp distributes pharmaceuticals and health and beauty products to medical institutions and retailers... Show more
The Moving Average Convergence Divergence (MACD) for MEPDF turned positive on July 22, 2025. Looking at past instances where MEPDF's MACD turned positive, the stock continued to rise in of 13 cases over the following month. The odds of a continued upward trend are .
The Aroon Indicator for MEPDF entered a downward trend on August 08, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MEPDF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.783) is normal, around the industry mean (8.544). P/E Ratio (12.110) is within average values for comparable stocks, (80.609). MEPDF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.537). Dividend Yield (0.027) settles around the average of (0.031) among similar stocks. P/S Ratio (0.133) is also within normal values, averaging (141.100).
Industry MedicalDistributors
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
NVDS | 11.77 | 0.16 | +1.38% |
Tradr 1.5X Short NVDA Daily ETF | |||
XXCH | 28.14 | N/A | N/A |
Direxion Daily MSCI Em Mkt Ex Chn Bl 2X | |||
STRV | 41.62 | -0.13 | -0.31% |
Strive 500 ETF | |||
KBWY | 15.54 | -0.05 | -0.32% |
Invesco KBW Premium Yield Eq REIT ETF | |||
OWNB | 30.29 | -0.71 | -2.29% |
Bitwise Bitcoin Standard Corporations ETF |
A.I.dvisor tells us that MEPDF and COSM have been poorly correlated (+12% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MEPDF and COSM's prices will move in lockstep.
Ticker / NAME | Correlation To MEPDF | 1D Price Change % | ||
---|---|---|---|---|
MEPDF | 100% | N/A | ||
COSM - MEPDF | 12% Poorly correlated | +1.20% | ||
MAHLY - MEPDF | 9% Poorly correlated | N/A | ||
SHPMF - MEPDF | 2% Poorly correlated | N/A | ||
PDRX - MEPDF | 0% Poorly correlated | N/A | ||
ARRJF - MEPDF | 0% Poorly correlated | N/A | ||
More |